dc.contributor.author | Cortellini, A | |
dc.contributor.author | Dettorre, GM | |
dc.contributor.author | Dafni, U | |
dc.contributor.author | Aguilar-Company, J | |
dc.contributor.author | Castelo-Branco, L | |
dc.contributor.author | Lambertini, M | |
dc.contributor.author | Gennatas, S | |
dc.contributor.author | Angelis, V | |
dc.contributor.author | Sita-Lumsden, A | |
dc.contributor.author | Rogado, J | |
dc.contributor.author | Pedrazzoli, P | |
dc.contributor.author | Viñal, D | |
dc.contributor.author | Prat, A | |
dc.contributor.author | Rossi, M | |
dc.contributor.author | Berardi, R | |
dc.contributor.author | Alonso-Gordoa, T | |
dc.contributor.author | Grisanti, S | |
dc.contributor.author | Dimopoulou, G | |
dc.contributor.author | Queirolo, P | |
dc.contributor.author | Pradervand, S | |
dc.contributor.author | Bertuzzi, A | |
dc.contributor.author | Bower, M | |
dc.contributor.author | Arnold, D | |
dc.contributor.author | Salazar, R | |
dc.contributor.author | Tucci, M | |
dc.contributor.author | Harrington, KJ | |
dc.contributor.author | Mazzoni, F | |
dc.contributor.author | Mukherjee, U | |
dc.contributor.author | Tsourti, Z | |
dc.contributor.author | Michielin, O | |
dc.contributor.author | Pommeret, F | |
dc.contributor.author | Brunet, J | |
dc.contributor.author | Vincenzi, B | |
dc.contributor.author | Tonini, G | |
dc.contributor.author | Patriarca, A | |
dc.contributor.author | Biello, F | |
dc.contributor.author | Krengli, M | |
dc.contributor.author | Tabernero, J | |
dc.contributor.author | Pentheroudakis, G | |
dc.contributor.author | Gennari, A | |
dc.contributor.author | Peters, S | |
dc.contributor.author | Romano, E | |
dc.contributor.author | Pinato, DJ | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-01-04T13:43:28Z | |
dc.date.available | 2023-01-04T13:43:28Z | |
dc.date.issued | 2022-11-01 | |
dc.identifier | ARTN e005732 | |
dc.identifier | jitc-2022-005732 | |
dc.identifier.citation | Journal for ImmunoTherapy of Cancer, 2022, 10 (11), pp. e005732 - | en_US |
dc.identifier.issn | 2051-1426 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5637 | |
dc.identifier.eissn | 2051-1426 | |
dc.identifier.eissn | 2051-1426 | |
dc.identifier.doi | 10.1136/jitc-2022-005732 | |
dc.description.abstract | BACKGROUND: As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. METHODS: In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European Society for Medical Oncology (ESMO) CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19. FINDINGS: The study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30) of 23.6% (95% CI 17.8 to 30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p<0.0001), requirement of oxygen therapy (15.8% vs 41.5%, p=0.0030), COVID-19 complication rate (11.9% vs 34.6%, p=0.0040), with a reduced need for COVID-19-specific therapy (26.3% vs 57.9%, p=0.0004) compared with unvaccinated patients. Inverse probability of treatment weighting (IPTW)-fitted multivariable analysis, following a clustered-robust correction for the data source (OnCovid vs ESMO CoCARE), confirmed that vaccinated patients experienced a decreased risk of death at 30 days (adjusted OR, aOR 0.08, 95% CI 0.01 to 0.69).Overall, 38 patients (15.8%) experienced at least one irAE of any grade at any time prior to COVID-19, at a median time of 3.2 months (range 0.13-48.7) from COVID-19 diagnosis. IrAEs occurred independently of baseline characteristics except for primary tumor (p=0.0373) and were associated with a significantly decreased CFR30 (10.8% vs 26.0%, p=0.0462) additionally confirmed by the IPTW-fitted multivariable analysis (aOR 0.47, 95% CI 0.33 to 0.67). Patients who experienced irAEs also presented a higher median absolute lymphocyte count at COVID-19 (1.4 vs 0.8 109 cells/L, p=0.0098). CONCLUSION: Anti-SARS-CoV-2 vaccination reduces morbidity and mortality from COVID-19 in ICI recipients. History of irAEs might identify patients with pre-existing protection from COVID-19, warranting further investigation of adaptive immune determinants of protection from SARS-CoV-2. | |
dc.format | Print | |
dc.format.extent | e005732 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | BMJ PUBLISHING GROUP | en_US |
dc.relation.ispartof | Journal for ImmunoTherapy of Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | COVID-19 | |
dc.subject | Cytotoxicity, Immunologic | |
dc.subject | Immunogenicity, Vaccine | |
dc.subject | Immunotherapy | |
dc.subject | Vaccination | |
dc.subject | Humans | |
dc.subject | Immune Checkpoint Inhibitors | |
dc.subject | COVID-19 | |
dc.subject | COVID-19 Testing | |
dc.subject | SARS-CoV-2 | |
dc.subject | Medical Oncology | |
dc.subject | Neoplasms | |
dc.subject | Registries | |
dc.title | Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-10-17 | |
dc.date.updated | 2023-01-04T13:42:35Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1136/jitc-2022-005732 | en_US |
rioxxterms.licenseref.startdate | 2022-11-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36450384 | |
pubs.issue | 11 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1136/jitc-2022-005732 | |
pubs.volume | 10 | |
icr.researchteam | Targeted Therapy | en_US |
dc.contributor.icrauthor | Harrington, Kevin | |
icr.provenance | Deposited by Mr Arek Surman on 2023-01-04. Deposit type is initial. No. of files: 1. Files: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer a joint analysis of OnCov.pdf | |